Laying out human pharmaceuticals, making external investments in Shi Zhi Yuan Company.
The genetically engineered subunit vaccine for swine fever (CHO-133D) has obtained a product approval number.
2024
2024
Inactivated vaccine for bovine lumpy skin disease, pseudorabies virus gB competitive ELISA antibody detection kit for pigs.
ELISA antibody detection kit for Seneca virus type A in pigs is on the market for sale.
The genetically engineered subunit vaccine for swine fever has obtained a Class III new veterinary drug certificate.
Construction of the mRNA production workshop has started.
2023
2023
Building a veterinary mRNA technology platform.
The inactivated vaccine for bovine lumpy skin disease has passed the emergency evaluation of the Ministry of Agriculture and Rural Affairs.
The FMD vaccine (for cattle and sheep) has obtained an approval number.
The diagnostic reagent for FMD virus in cattle and sheep has obtained a product approval number.
The diagnostic reagent for Seneca virus type A in pigs has obtained a Class II new veterinary drug certificate
2022
2022
The "one body, two wings" product strategy has been formed.
The cell suspension culture virus subunit vaccine production line has passed GMP acceptance.
Diagnostic products have been launched.
The porcine circovirus vaccine has obtained a product approval number.
2021
2021
The subunit vaccine for Porcine circovirus type 2 has obtained a new veterinary drug registration certificate.
The bivalent synthetic peptide vaccine for Bovine FMD types O and A has obtained a new veterinary drug certificate.
The FMD inactivated vaccine production line using cell suspension culture has passed the new version of veterinary GMP acceptance. The FMD synthetic peptide vaccine production line has passed the new version of veterinary GMP acceptance.
Shenlian Biomedical's molecular biology diagnostic products production line has passed GMP acceptance.
Shenlian Biomedical's products from its first public offering and fundraising projects have officially started production.
2020
2020
The FMD(suspension) production line has passed the biosafety level 3 protection acceptance for veterinary vaccines.
Shenlian Biomedical has been honored with the Global Scientific and Technological Innovation Advancement Award.
The veterinary product "African Swine Fever Virus Fluorescent PCR Nucleic Acid Detection Kit" has been approved for production by the Ministry of Agriculture and Rural Affairs.
2019
2019
The first company in the industry to be listed on the STAR Market, stock code 688098.
Shenlian Biomedical's immunology diagnostic products production line passed GMP inspection.
The avian influenza virus H7 subtype fluorescent RT-PCR detection kit obtained a new veterinary drug certificate.
2018
2018
The bivalent synthetic peptide vaccine for swine FMD types O and A has obtained a new veterinary drug certificate.
2017
2017
The bivalent inactivated vaccine for swine FMD types O and A, developed by Shenlian Biomedical, has obtained a Class I new veterinary drug certificate.
2016
2016
Awarded the Second Prize of National Science and Technology Progress Award.
2015
2015
Shenlian Biomedical underwent shareholding system reform.
Shenlian Biomedical's trademark was awarded "Famous Trademark of Shanghai".
2014
2014
Shanghai Shen Lian Biomedical Corporation Lanzhou Branch was established.
The swine FMD type O synthetic peptide vaccine (triple-component) obtained a new veterinary drug certificate.
2009
2009
The swine FMD type O synthetic peptide vaccine (dual-component) product was launched.
2007
2007
The first domestic production line for FMD synthetic peptide vaccine passed GMP inspection.
The first domestic FMD synthetic peptide vaccine product was launched.
2004
2004
The synthetic peptide vaccine for swine FMD type O has obtained a Class I new veterinary drug certificate, marking the first synthetic peptide vaccine for FMD in China.
2001
2001
Shanghai Shen Lian Biomedical Corporation was established.
